Sun Pharmaceutical Industries (Sun Pharma) announced on 8 February 2013 that it had given up on its effort to buy the remaining stock of Taro Pharmaceutical Industries (Taro) for about US$685 million after Taro shareholders held out for a higher price.
Sun Pharma ends attempt to gain full control of Taro
Home/Pharma News
|
Posted 22/02/2013
0
Post your comment
India-based generics manufacturer Sun Pharma only managed to gain a controlling stake in Israel’s Taro in September 2010 after a prolonged legal battle [1], and currently holds 66% of Taro’s shares [2].
Sun Pharma offered in October 2011 to buy all outstanding shares of Taro, not currently held by Sun Pharma, at a price of US$24.50 per share [2]. However, despite this offer being increased by almost 60% to US$39.50 per share in August 2012 [3], Taro shareholders still rejected the deal. The shareholders already believed in October 2011 that a fair value for Taro would have been at least US$48.50 per share [2], which Sun Pharma was not willing to offer.
Sun Pharma has been battling to take over Taro since May 2007, when Taro was a struggling company and Sun Pharma first bought shares in Taro [1]. Since that time, however, Taro has become profitable, with its share price quickly surpassed the offer from Sun Pharma. Taro’s closing share price on the New York Stock Exchange on 7 February 2013 was US$50.55.
‘As earnings keep coming in stronger and stronger for Taro, there was obviously a lot of disconnect with the price Sun [Pharma] was willing to offer,’ IDFC Securities analyst Nitin Agarwal told Bloomberg. He added that it was ‘fairly unlikely that the deal would have gone through’.
The two companies stated that the termination of the merger agreement ‘was in the best interest of the respective companies and shareholders’.
Reference
1. GaBI Online - Generics and Biosimilars Initiative. Sun Pharma finally wins battle for Taro [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Feb 22]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-finally-wins-battle-for-Taro
2. GaBI Online - Generics and Biosimilars Initiative. Sun Pharma offers to buy remaining Taro shares [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Feb 22]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-offers-to-buy-remaining-Taro-shares
3. GaBI Online - Generics and Biosimilars Initiative. Sun Pharma finally gains full control of Taro [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Feb 22]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-finally-gains-full-control-of-Taro
Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Source: Sun Pharma, Taro
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Biosimilar race: Sandoz expands pipeline with Henlius, Teva secures ocrelizumab candidate
Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
Amgen expansion, BioNTech retrenchment highlight diverging manufacturing strategies in biopharma
Biosimilar race: Sandoz expands pipeline with Henlius, Teva secures ocrelizumab candidate
Home/Pharma News Posted 02/09/2026
Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Home/Pharma News Posted 20/08/2026
Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
Home/Pharma News Posted 12/06/2026
Amgen expansion, BioNTech retrenchment highlight diverging manufacturing strategies in biopharma
Home/Pharma News Posted 05/06/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment